There is no firm evidence to support the use of PPI infusions outside this indication and published guidelines vary in their advice. Aims: The aims of this study were to assess the prescribing practice of parenteral PPI’s for acute upper gastrointestinal bleeding (AUGB) in a large metropolitan healthcare network, and to identify factors that influence the decision to administer these drugs. Methods: Patients were identified from the Haematemesis & Melaena database maintained by the Eastern Health Gastroenterology Service from August 2013 to January 2014. Exclusion criteria were age <18 and diagnosis other than upper GI bleeding. Data was collated from review

of electronic patient records. Analysis of the data was performed using T-tests and Fisher’s Exact tests with p values <0.05 considered significant. Results: A total of 113 patients were included (mean 71 (95%CI 67.2–74.0) years, 39% female, GS-1101 molecular weight median post-endoscopy Rockall 4 (Table 1)). A PPI infusion Erlotinib cost was prescribed

in 86% (97/113) of patients, with 94% (91/97) receiving this prior to endoscopy. Fourteen patients (14.4%) prescribed a PPI infusion did not go on to endoscopy. Patients were more likely to receive a PPI infusion if their pre-endoscopic Rockall Score was >4 (43/45 vs. 48/68, P < 0.05). There was no relationship between haemoglobin <90 mg/L at presentation and the decision to commence IV PPI (48/64 vs. 43/49, P = 0.1) or between those who presented with coffee-ground vomiting and those 上海皓元 who presented with other features of acute bleeding (20/23 vs. 71/90, P = 0.56). A PPI infusion was started or continued in 56% (52/93) of patients who underwent endoscopy. Of these, only fourteen (27%) underwent EHT for peptic ulceration,

twenty-one (40%) underwent EHT for non-ulcer disease and seventeen (33%) had no EHT. Patients were more likely to have their PPI infusion continued if they had undergone EHT (35/39 v 17/54, P < 0.05) regardless of endoscopic findings. All patients who underwent EHT for peptic ulcer received a PPI infusion (14/14). Table 1: Summary of patient characteristics. Patient characteristics Mean (Range) Age 70.6 years (21–101) Hb at presentation 97.5 mg/L (39–184) Transfusion requirements 2.1 units (0–17) Time to first endoscopy 26.6 hours (0.8–260.5) Length of Stay (LOS) 6.6 day (1–30) Pre-endoscopic Rockall Score 3 (median) Post – endoscopic Rockall Score 4 (median) Conclusion: All patients in whom there was a clear indication received an IV PPI infusion, but a quarter of the prescribed infusions were deemed unnecessary and 1 in 10 infusions were prescribed to patients not requiring endoscopy. Moreover, the vast majority of infusions were commenced prior to endoscopy, a practice which is not supported by published guidelines.